According to Michaud et al., in HNSCC, increased BCL-2 expression often correlates with chemoresistance and tumor survival, while BAX activation may represent a cellular attempt to induce apoptosis in response to therapeutic stress. The gene discussed is BAX; the disease is head and neck squamous cell carcinoma.